Xebio Holdings Co. Ltd. said its normalized net income for the fiscal fourth quarter ended March 31 was ¥3.57 per share, a decline of 69.2% from ¥11.58 per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥161.3 million, a decline of 69.1% from ¥521.9 million in the year-earlier period.
The normalized profit margin dropped to 0.3% from 1.0% in the year-earlier period.
Total revenue climbed year over year to ¥54.38 billion from ¥53.05 billion, and total operating expenses increased on an annual basis to ¥54.17 billion from ¥52.59 billion.
Reported net income came to a loss of ¥1.24 billion, or a loss of ¥27.47 per share, compared to a loss of ¥967.4 million, or a loss of ¥21.45 per share, in the prior-year period.
For the year, the company's normalized net income totaled ¥88.47 per share, a decrease from ¥92.58 per share in the prior year.
Normalized net income was ¥4.00 billion, a decrease from ¥4.18 billion in the prior year.
Full-year total revenue increased 5.1% from the prior-year period to ¥221.39 billion from ¥210.67 billion, and total operating expenses increased on an annual basis to ¥215.22 billion from ¥205.02 billion.
The company said reported net income rose on an annual basis to ¥2.12 billion, or ¥46.79 per share, in the full year, from ¥2.08 billion, or ¥46.17 per share.
As of June 29, US$1 was equivalent to ¥102.64.